Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...
The U.S. Food and Drug Administration expanded the use of Rhythm Pharmaceuticals’  therapy for a rare form of obesity ​caused ...
A major study links Wegovy to a rare form of sudden vision loss, and finds men may face three times the risk of women.
The FDA has approved a new higher-dose version of injectable semaglutide (Wegovy HD, Novo Nordisk) for both weight loss and ...
It’s frustrating to watch, given my field of study.
Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight ...
Learn how people with polymyalgia rheumatica can manage symptoms with self-injections. Get best practices for self-injections ...